High Neutrophil-to-Lymphocyte Ratio and Patients With Hemodialysis

To explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hemodialysis Patient

Age range

18 month and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hemodialysis Unit

Sohag, Sohag Governorate, Egypt

Location contact

ali taha, professor of internal medicine

CONTACT

[email protected]

01005871047

marwa zanaty, lecture of internal medicine

CONTACT

01007100970

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All cases with age ≥ 18 years from both sexes female and male, having end-stage renal disease (ESRD), who have been on hemodialysis for at least three months and divided to 4 groups according to the median of NLR and PLR

Exclusion criteria

• Patients aged < 18 years old.

Patient with autoimmune disease.
Patient with liver cirrhosis.
Patients with immunodeficiency.
Patients with malignancy.

Treatment and study plan

neutrophil lymphocyte ratio and platelet lymphocyte ratio

Other

explore the role of neutrophil-to-lymphocyte ratio ( NLR ) and platelet-to-lymphocyte ratio ( PLR ) in predicting mortality in hemodialysis (HD) patients

Primary outcomes

Mortality

Time frame: 6 months

The primary outcome measures in the study "High Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Are Associated with Poor Survival in Patients with Hemodialysis" is :- All-cause mortality, encompassing death from any cause These is the endpoint used to evaluate the prognostic significance of NLR and PLR in hemodialysis patients.

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

High Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Are Associated With Poor Survival in Patients With Hemodialysis

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jul 17, 2025
Registry last updated: Jul 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting